AN2 Therapeutics, Inc., (ANTX): Price and Financial Metrics


AN2 Therapeutics, Inc., (ANTX): $9.63

-0.19 (-1.93%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ANTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ANTX Stock Price Chart Interactive Chart >

Price chart for ANTX

ANTX Price/Volume Stats

Current price $9.63 52-week high $23.58
Prev. close $9.82 52-week low $6.88
Day low $9.58 Volume 12,200
Day high $10.05 Avg. volume 26,092
50-day MA $11.36 Dividend yield N/A
200-day MA $11.85 Market Cap 186.85M

AN2 Therapeutics, Inc., (ANTX) Company Bio


AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.


ANTX Latest News Stream


Event/Time News Detail
Loading, please wait...

ANTX Latest Social Stream


Loading social stream, please wait...

View Full ANTX Social Stream

Latest ANTX News From Around the Web

Below are the latest news stories about AN2 THERAPEUTICS INC that investors may wish to consider to help them evaluate ANTX as an investment opportunity.

AN2 Therapeutics GAAP EPS of -$0.61

  • AN2 Therapeutics press release (NASDAQ:ANTX): Q4 GAAP EPS of -$0.61.
  • Cash, cash equivalents and investments totaled $99.3 million at December 31, 2022,
  • Net loss: For the three months and full year ended December 31, 2022 net loss was $11.8 million and $41.0 million, respectively.
  • Interest and other income, net for the full year 2022 was $1.3 million, compared to $0.03 mill...

    Seeking Alpha | March 29, 2023

AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

MENLO PARK, Calif., March 29, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2022.

Yahoo | March 29, 2023

AN2 Therapeutics to Participate in Upcoming Investor Conferences

MENLO PARK, Calif., February 28, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in March.

Yahoo | February 28, 2023

AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

MENLO PARK, Calif., January 31, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the SVB Securities Global Biopharma Conference.

Yahoo | January 31, 2023

AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | December 4, 2022

Read More 'ANTX' Stories Here

ANTX Price Returns

1-mo -15.53%
3-mo 1.05%
6-mo -44.59%
1-year -36.10%
3-year N/A
5-year N/A
YTD 1.05%
2022 N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8558 seconds.